Moderna stock slides 11.5% premarket after earnings miss by a wide margin and company cuts sales outlook by up to $3 billion

Moderna Inc. shares plunged 11% in premarket trade Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.